Throcare Technologies Ltd (BSE: 539871) is a Navi Mumbai, Maharashtra-based company in the Medical Diagnostic Centres industry. With a market capitalisation of ₹7,737 Cr, it ranks #675 by market cap among the 6,137 Indian listed companies on FinBizNet, and #3 of 18 in Medical Diagnostic Centres. At ₹463.15 (as of 25 Oct 2026), the share price is 30.0% below its 52-week high of ₹662.00 and 35.2% above its 52-week low of ₹342.55. The share price is up 8.9% over one year and down 17.9% over three months.
| Current Price | ₹463.15 |
|---|---|
| Market Cap | ₹7,737 Cr |
| BSE Code | 539871 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Services > Medical Diagnostic Centres |
| P/E Ratio | 46.3 |
| Return on Equity | 28.74% |
| Return on Assets | 17.69% |
| 52-Week Range | ₹342.55 – ₹662.00 |
| 1-Year Price Change | +8.9% |
| 3-Month Price Change | -17.9% |
| Beta (1Y) | 0.96 |
| Dividend Yield | 2.96% |
| Headquarters | Navi Mumbai, Maharashtra |
| Website | www.thyrocare.com |
| Revenue | ₹240 Cr |
|---|---|
| Net Profit | ₹51 Cr |
| Net Margin | 21.1% |
| EPS (Basic) | ₹3.23 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of testing equipment and consumables; and glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
1. Diagnostic Testing Services-This segment provides laboratory testing services. 2. Imaging Services-This segment provides PET-CT scanning services; and sells radio pharmaceuticals used in imaging services. 3. Others-This segment engages in trading and other related business activities. 4. Unallocable Assets-0
1. Diagnostic Testing Services-93.2% 2. Imaging Services-6.4% 3. Others-0.4%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Vijaya Diagnostic Centre Limited | ₹14,231 Cr | 81.5 | 19.70% | ₹231 Cr | +40.7% |
| Metropolis Healthcare Limited | ₹11,002 Cr | 56.7 | 13.37% | ₹450 Cr | +7.3% |
| Throcare Technologies Ltd | ₹7,737 Cr | 46.3 | 28.74% | ₹240 Cr | +8.9% |
| Dr. Agarwal'S Eye Hospital Ltd | ₹2,465 Cr | 34.5 | 25.22% | — | +20.0% |
| Krsnaa Diagnostics Ltd | ₹1,730 Cr | 16.6 | 10.89% | ₹236 Cr | -38.8% |
| SURAKSHA DIAGNOSTIC LIMITED | ₹1,597 Cr | 48.2 | 13.84% | ₹88 Cr | -0.3% |
| Gaudium IVF and Women Health Limited | ₹738 Cr | 25 | 16.08% | ₹19 Cr | — |
| Chandan Healthcare Limited | ₹583 Cr | 21.5 | — | ₹81 Cr | — |
| Star Imaging And Path Lab Limi | ₹136 Cr | 6.2 | — | — | -43.0% |
Listed by market capitalisation. Ratios are shown for context only.
Throcare Technologies Ltd is trading at ₹463.15, with a market capitalisation of ₹7,737 Cr.
Throcare Technologies Ltd operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Medical Diagnostic Centres).
Throcare Technologies Ltd has a P/E of 46.3 and a return on equity of 28.74%.
Throcare Technologies Ltd is listed on the BSE under the scrip code 539871.
Throcare Technologies Ltd's share price is up 8.9% over one year and down 17.9% over three months. Its 52-week range is ₹342.55 to ₹662.00.
In Q1 FY27, Throcare Technologies Ltd reported revenue of ₹240 Cr and net profit of ₹51 Cr, with basic EPS of ₹3.23 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.